vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $47.7M, roughly 1.2× IRONWOOD PHARMACEUTICALS INC). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -83.0%, a 78.2% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -47.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
IRWD vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $57.3M |
| Net Profit | $-2.3M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 14.3% | -82.2% |
| Net Margin | -4.8% | -83.0% |
| Revenue YoY | -47.3% | 36.9% |
| Net Profit YoY | -200.9% | -9.6% |
| EPS (diluted) | $0.01 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $57.3M | ||
| Q3 25 | $122.1M | $51.3M | ||
| Q2 25 | $85.2M | $48.5M | ||
| Q1 25 | $41.1M | $32.7M | ||
| Q4 24 | $90.5M | $41.8M | ||
| Q3 24 | $91.6M | $33.3M | ||
| Q2 24 | $94.4M | $29.1M | ||
| Q1 24 | $74.9M | $26.0M |
| Q4 25 | $-2.3M | $-47.5M | ||
| Q3 25 | $40.1M | $-52.9M | ||
| Q2 25 | $23.6M | $-46.6M | ||
| Q1 25 | $-37.4M | $-49.5M | ||
| Q4 24 | $2.3M | $-43.3M | ||
| Q3 24 | $3.6M | $-43.6M | ||
| Q2 24 | $-860.0K | $-32.3M | ||
| Q1 24 | $-4.2M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 14.3% | -82.2% | ||
| Q3 25 | 61.8% | -102.6% | ||
| Q2 25 | 53.2% | -93.4% | ||
| Q1 25 | -70.7% | -143.7% | ||
| Q4 24 | 34.8% | -98.6% | ||
| Q3 24 | 28.0% | -132.0% | ||
| Q2 24 | 26.5% | -139.2% | ||
| Q1 24 | 14.7% | -538.7% |
| Q4 25 | -4.8% | -83.0% | ||
| Q3 25 | 32.8% | -103.1% | ||
| Q2 25 | 27.7% | -96.1% | ||
| Q1 25 | -90.9% | -151.4% | ||
| Q4 24 | 2.5% | -103.6% | ||
| Q3 24 | 4.0% | -131.2% | ||
| Q2 24 | -0.9% | -110.9% | ||
| Q1 24 | -5.6% | -544.4% |
| Q4 25 | $0.01 | $-0.73 | ||
| Q3 25 | $0.23 | $-0.82 | ||
| Q2 25 | $0.14 | $-0.75 | ||
| Q1 25 | $-0.23 | $-0.81 | ||
| Q4 24 | $0.03 | $-0.71 | ||
| Q3 24 | $0.02 | $-0.73 | ||
| Q2 24 | $-0.01 | $-0.55 | ||
| Q1 24 | $-0.03 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-261.8M | $139.1M |
| Total Assets | $396.9M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $388.9M | ||
| Q3 25 | $140.4M | $416.1M | ||
| Q2 25 | $92.9M | $291.0M | ||
| Q1 25 | $108.5M | $314.5M | ||
| Q4 24 | $88.6M | $320.6M | ||
| Q3 24 | $88.2M | $298.4M | ||
| Q2 24 | $105.5M | $319.1M | ||
| Q1 24 | $121.5M | $201.2M |
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $398.3M | — |
| Q4 25 | $-261.8M | $139.1M | ||
| Q3 25 | $-264.2M | $148.8M | ||
| Q2 25 | $-308.2M | $-11.9M | ||
| Q1 25 | $-334.1M | $18.9M | ||
| Q4 24 | $-301.3M | $21.7M | ||
| Q3 24 | $-311.3M | $11.2M | ||
| Q2 24 | $-321.7M | $39.3M | ||
| Q1 24 | $-330.5M | $61.6M |
| Q4 25 | $396.9M | $480.2M | ||
| Q3 25 | $396.1M | $506.9M | ||
| Q2 25 | $342.9M | $372.7M | ||
| Q1 25 | $327.2M | $386.7M | ||
| Q4 24 | $350.9M | $392.3M | ||
| Q3 24 | $389.5M | $363.6M | ||
| Q2 24 | $395.6M | $381.8M | ||
| Q1 24 | $438.8M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $-25.4M |
| Free Cash FlowOCF − Capex | $74.6M | — |
| FCF MarginFCF / Revenue | 156.3% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $-25.4M | ||
| Q3 25 | $47.6M | $-26.6M | ||
| Q2 25 | $-15.1M | $-23.3M | ||
| Q1 25 | $20.0M | $-40.4M | ||
| Q4 24 | $15.2M | $-18.8M | ||
| Q3 24 | $9.9M | $-25.2M | ||
| Q2 24 | $33.5M | $-29.1M | ||
| Q1 24 | $45.0M | $-40.7M |
| Q4 25 | $74.6M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $-15.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | 156.3% | — | ||
| Q3 25 | 39.0% | — | ||
| Q2 25 | -17.7% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 35.4% | — | ||
| Q1 24 | 60.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | -0.64× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.74× | — | ||
| Q3 24 | 2.71× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
